Irbesartan Accord

Irbesartan, the active ingredient in Irbesartan Accord, is an angiotensin II receptor blocker presented as a tablet for oral use. It treats hypertension and helps protect kidney function in patients with diabetic nephropathy. GNH USA supplies Irbesartan Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan is an ARB that acts on the renin‑angiotensin system to control blood pressure and renal outcomes. - Hypertension: lowers systolic and diastolic blood pressure in adult patients. - Diabetic nephropathy: slows the progression of kidney damage in type 2 diabetes. - Cardiovascular risk reduction: contributes to lower incidence of cardiovascular events in patients with hypertension.

Common side effects are generally mild and reversible.

Common Side Effects: - Dizziness: sensation of light‑headedness, especially after standing. - Headache: mild to moderate intensity. - Fatigue: feeling of tiredness without exertion. - Hyperkalemia: elevated blood potassium levels.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, tongue, or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure causing faintness. - Acute renal failure: sudden loss of kidney function. - Hepatic injury: abnormal liver enzymes or jaundice.

Before initiating therapy, clinicians should assess individual risk factors and monitor relevant parameters. - Blood pressure monitoring: check regularly to avoid excessive hypotension. - Renal function: assess serum creatinine and eGFR before and during treatment. - Electrolytes: monitor potassium levels, especially with concomitant potassium‑sparing agents. - Pregnancy: avoid use in pregnancy due to potential fetal toxicity. - Hepatic impairment: use with caution and adjust if liver disease is present. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Irbesartan may interact with several medicines, requiring attention to dosage and monitoring.

Major Interactions (Avoid): - Aliskiren in diabetic patients: combined use can increase renal risk. - Dual therapy with ACE inhibitors or other ARBs: may cause excessive potassium rise and renal impairment. - Potassium supplements or potassium‑sparing diuretics: risk of hyperkalemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may enhance antihypertensive effect, watch for hypotension. - Lithium: increased lithium levels, monitor for toxicity. - Cyclosporine: may raise serum creatinine, adjust dose as needed. - NSAIDs: can blunt blood‑pressure‑lowering effect, monitor response.